Back to CSTLView Full LandscapeView full pipeline
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
3 competitors in Dystrophic Epidermolysis Bullosa
KRYSOpen Label Topical Beremagene Geperpavec (B-VEC)
Phase 3KRYSTopical beremagene geperpavec
Phase 3KRYSKB803
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Autologous Human Fibroblast (azficel-T)Phase 3
Bilateral Nasolabial Fold Wrinkles
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)Phase 3
Recessive Dystrophic Epidermolysis Bullosa
Autologous Human Fibroblasts (azficel-T)Phase 3
Acne Scarring of the Face
Azficel-T (autologous fibroblasts)Phase 2
Dysphonia Resulting From Vocal Fold Scarring
diacerein 1% ointmentPhase 2
Epidermolysis Bullosa
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts